JeanMarie Guenot, PhD is a successful business executive with more than two decades of experience in the biotechnology and pharmaceutical industries. She has worked with a number of companies in various stages, and in both private and public sectors. Her business development skills and experience in alliance and project management have contributed to the long-term success of a number of corporations.
JeanMarie Guenot also has expertise in building and rebuilding organizations and has worked in a number of therapeutic areas. Most recently, Guenot has worked in ophthalmology as the key business and operating officer for SKS Ocular. Dr. Guenot is also responsible for founding and managing SKS Ocular, which is a start-up ophthalmic organization, and SKS Ocular 1. SKS Ocular 1 is the first of five portfolio companies with a focus on sustained release ocular drug deliver and dry AMD. The company provides therapies and technology that treats ocular inflammation, glaucoma and macular degeneration. Guenot began her career at Atlas Venture, where she helped to create life science companies and supervise venture capital investments. Guenot then started her career in science when she became the principal scientist at Hoffman-La Roche for the company’s preclinical R&D.
JeanMarie Guenot served as the business advisor for Hoffman-La Roche from 2008 to 2009 in both Basel and Shanghai. Before this, she was the VP of Corporate and Business Development for PDL BioPharma, was in charge of alliance management, mergers and acquisitions for the commercial product and R&D portfolios for PDL.
Guenot also negotiated and spearheaded the Biogen Idec-PDL collaboration for development and commercialization, involving three autoimmune disease drug and cancer candidates. This transaction on guenotllc.com, which was worth $880 million, including an equity investment of $100 million in PDL and a candidate with indications. Profits were split between Hoffman-La Roche and Biogen Idec.
Guenot is also the recipient of the 2005 Innovative Bio-Partnering Award, presented by BioBusiness Network, and was a noted participant in the sale of commercial and manufacturing businesses for PDL. She has previously been a member of the Portfolio Management Committee and Executive Team for PDL as well. Dr. Guenot is also known for leading the Biogen Idec-PDL alliance and served as a member of the Joint Steering Committee for this partnership.